Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00943072 · ClinicalTrials.gov registry record · Phase 3
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
A Phase 3 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 189
- Enrollment target
NCT00943072 is a Phase 3 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 189 participants.
The verdict
NCT00943072, a Phase 3 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 189 participants
- Enrollment target
Study Summary
This is a phase 3 study to determine the efficacy of VEGF Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion.
Interventions
- DRUG Sham
- BIOLOGICAL VEGF Trap-Eye 2.0mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00943072
The ClinicalTrials.gov registry entry for NCT00943072 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT00943072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00943072 about?
NCT00943072 is a clinical study titled "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)". This is a phase 3 study to determine the efficacy of VEGF Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion.
What is the current status of trial NCT00943072?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 189 participants. The study started on 2009-07. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00943072?
The interventions under investigation include: Sham (DRUG), VEGF Trap-Eye 2.0mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00943072?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.